GLP-1s and PCOS: What the insulin resistance hype gets right and wrong

What did @haleighweaver5 actually say?

The creator shared a two-week update on stopping semaglutide (she calls it "zim big," likely Zepbound or a similar GLP-1 medication) before surgery. Her main symptom was headaches, which she attributed to either dehydration or blood sugar fluctuations. She also claimed that "microdosing" before stopping made her discontinuation experience gentler this time compared to a cold-stop about a year ago.

She was upfront about not being a medical authority here. This is personal experience content, not a protocol recommendation. She flagged dehydration as a possible alternative cause for her headaches, which is actually a reasonable hedge. The surgery-related pause requirement she described, specifically needing to stop at least two weeks before going under anesthesia, is also a real clinical guideline, not something she invented.

Does the science back this up?

Mostly, yes, with some important nuance. GLP-1 receptor agonists like semaglutide do contribute to glycemic regulation, and stopping them can lead to a rebound in postprandial glucose. But the magnitude depends heavily on whether someone has type 2 diabetes or insulin resistance without a diabetes diagnosis.

A 2022 trial by Wilding et al. in Diabetes, Obesity and Metabolism found that participants who stopped semaglutide regained weight and saw metabolic markers, including blood glucose, trend back toward baseline within weeks. That supports her intuition that blood sugar changes when you stop. However, the idea that blood sugar "spikes" acutely and directly causes headaches in non-diabetic patients is less well-supported. Headaches after GLP-1 discontinuation are not a consistently documented withdrawal symptom in clinical literature. Her dehydration explanation is honestly more plausible.

On the anesthesia point: the American Society of Anesthesiologists issued guidance in 2023 recommending pausing GLP-1 agonists before elective procedures due to concerns about delayed gastric emptying and aspiration risk. Her two-week pause aligns with that guidance.

What did they get wrong (or right)?

She got the anesthesia pause requirement right. The ASA guidance is real, and the two-week timeline she cited is consistent with current clinical recommendations for weekly-dosed GLP-1 medications.

Where she oversteps slightly is the causal chain: "your blood sugar probably is going to spike" is presented with more certainty than the evidence warrants for someone with PCOS and insulin resistance who may not have frank hyperglycemia to begin with. Blood sugar trending upward is plausible. A dramatic spike causing headaches is less established.

The "microdosing" claim is the weakest part of the video. She suggests that tapering down her dose before stopping made the discontinuation easier. Gradual dose reduction as a discontinuation strategy has face validity, but there is no published clinical trial specifically studying microdosing GLP-1s as an off-ramp protocol. This is anecdote, not evidence. It may work for her. It is not something viewers should take as a generalizable approach without talking to their prescriber.

• Anesthesia pause requirement: accurate and well-supported
• Blood sugar rising after stopping: plausible, somewhat supported
• Headaches from blood sugar spike: speculative, dehydration more likely
• Microdosing as easier discontinuation: unverifiable, no clinical trial support

What should you actually know?

If you are on a GLP-1 medication and have upcoming surgery, this video is a useful reminder that you need to tell your surgical team. The gastric emptying issue is serious. Aspiration under anesthesia is a real risk, not a theoretical one. Do not manage that timeline yourself based on a TikTok video, including this one.

On discontinuation symptoms more broadly: the research on what happens when people stop GLP-1s is still catching up to how widely these drugs are being prescribed. A 2022 paper by Rubino et al. in JAMA showed that stopping semaglutide led to substantial weight regain and reversal of metabolic improvements within a year. What that means for shorter pauses, like a two-week surgical hold, is less clear. Short-term metabolic disruption is possible but unlikely to be severe in most patients.

Headaches are common and have many causes. Attributing them to blood sugar changes without a glucometer reading is guesswork. If you are experiencing symptoms after stopping your medication, log them and bring them to your provider. Do not self-diagnose the mechanism based on social media.

Bottom line

This video is largely harmless and occasionally accurate. The creator is sharing her own experience, flagging uncertainty where it exists, and not telling anyone to copy her approach. That is better than a lot of GLP-1 content on this platform. The blood sugar spike narrative is a stretch, and the microdosing claim lacks any clinical backing. But the core message, that stopping a GLP-1 before surgery is required and that the experience can vary, is grounded in reality.